BioTime Reports Interim Results on Renevia™ Clinical Safety Trial

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), today announced that William Tew, Ph.D., BioTime’s Chief Commercial Officer will provide an update on the development of Renevia™ at an investor meeting in New York City. In his presentation, Dr. Tew will announce that enrollment in a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stable engraftment of transplanted cells, is complete.

Help employers find you! Check out all the jobs and post your resume.